Literature DB >> 11444978

Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains.

K A Carpenter1, R Schmidt, B von Mentzer, U Haglund, E Roberts, C Walpole.   

Abstract

The 37-amino acid calcitonin gene-related peptide (CGRP) is a potent endogenous vasodilator thought to be implicated in the genesis of migraine attack. CGRP antagonists may thus have therapeutic value for the treatment of migraine. The CGRP C-terminally derived peptide [D(31),P(34),F(35)]CGRP(27-37)-NH(2) was recently identified as a high-affinity hCGRP(1) receptor selective antagonist. Reasonable CGRP(1) affinity has also been demonstrated for several related analogues, including [D(31),A(34),F(35)]CGRP(27-37)-NH(2). In the study presented here, conformational and structural features in CGRP(27-37)-NH(2) analogues that are important for hCGRP(1) receptor binding were explored. Structure-activity studies carried out on [D(31),P(34),F(35)]CGRP(27-37)-NH(2) resulted in [D(31),P(34),F(35)]CGRP(30-37)-NH(2), the shortest reported CGRP C-terminal peptide analogue exhibiting reasonable hCGRP(1) receptor affinity (K(i) = 29.6 nM). Further removal of T(30) from the peptide's N-terminus greatly reduced receptor affinity from the nanomolar to micromolar range. Additional residues deemed critical for hCGRP(1) receptor binding were identified from an alanine scan of [A(34),F(35)]CGRP(28-37)-NH(2) and included V(32) and F(37). Replacement of the C-terminal amide in this same peptide with a carboxyl, furthermore, resulted in a greater than 50-fold reduction in hCGRP(1) affinity, thus suggesting a direct role for the amide moiety in receptor binding. The conformational properties of two classes of CGRP(27-37)-NH(2) peptides, [D(31),X(34),F(35)]CGRP(27-37)-NH(2) (X is A or P), were examined by NMR spectroscopy and molecular modeling. A beta-turn centered on P(29) was a notable feature consistently observed among active peptides in both series. This turn led to exposure of the critical T(30) residue to the surrounding environment. Peptides in the A(34) series were additionally characterized by a stable C-terminal helical turn that resulted in the three important residues (T(30), V(32), and F(37)) adopting consistent interspatial positions with respect to one another. Peptides in the P(34) series were comparatively more flexible at the C-terminus, although a large proportion of the [D(31),P(34),F(35)]CGRP(27-37)-NH(2) calculated conformers contained a gamma-turn centered on P(34). These results collectively suggest that turn structures at both the C-terminus and N-terminus of CGRP(27-37)-NH(2) analogues may help to appropriately orient critical residues (T(30), V(32), and F(37)) for hCGRP(1) receptor binding.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444978     DOI: 10.1021/bi0102860

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

1.  Solution state structures of human pancreatic amylin and pramlintide.

Authors:  John R Cort; Zhihong Liu; Gregory M Lee; K N L Huggins; Susan Janes; Kathryn Prickett; Niels H Andersen
Journal:  Protein Eng Des Sel       Date:  2009-07-12       Impact factor: 1.650

Review 2.  Receptor Activity-Modifying Proteins (RAMPs): New Insights and Roles.

Authors:  Debbie L Hay; Augen A Pioszak
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

3.  Three-dimensional structure and orientation of rat islet amyloid polypeptide protein in a membrane environment by solution NMR spectroscopy.

Authors:  Ravi Prakash Reddy Nanga; Jeffrey R Brender; Jiadi Xu; Kevin Hartman; Vivekanandan Subramanian; Ayyalusamy Ramamoorthy
Journal:  J Am Chem Soc       Date:  2009-06-17       Impact factor: 15.419

Review 4.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 5.  Structure-activity relationships for α-calcitonin gene-related peptide.

Authors:  Harriet A Watkins; Dan L Rathbone; James Barwell; Debbie L Hay; David R Poyner
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage.

Authors:  Stelios Kokkoris; Peter Andrews; David J Webb
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-15       Impact factor: 5.555

7.  Structural Basis for Receptor Activity-Modifying Protein-Dependent Selective Peptide Recognition by a G Protein-Coupled Receptor.

Authors:  Jason M Booe; Christopher S Walker; James Barwell; Gabriel Kuteyi; John Simms; Muhammad A Jamaluddin; Margaret L Warner; Roslyn M Bill; Paul W Harris; Margaret A Brimble; David R Poyner; Debbie L Hay; Augen A Pioszak
Journal:  Mol Cell       Date:  2015-05-14       Impact factor: 17.970

8.  Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.

Authors:  Chia Lin Chang; Sheau Yu Teddy Hsu
Journal:  PLoS One       Date:  2019-05-31       Impact factor: 3.240

Review 9.  Alpha-Calcitonin Gene Related Peptide: New Therapeutic Strategies for the Treatment and Prevention of Cardiovascular Disease and Migraine.

Authors:  Ambrish Kumar; Maelee Williamson; Andrew Hess; Donald J DiPette; Jay D Potts
Journal:  Front Physiol       Date:  2022-02-11       Impact factor: 4.566

10.  New Engineered-Botulinum Toxins Inhibit the Release of Pain-Related Mediators.

Authors:  Minhong Tang; Jianghui Meng; Jiafu Wang
Journal:  Int J Mol Sci       Date:  2019-12-30       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.